Regulatory enzymes of mitochondrial β‐oxidation as targets for treatment of the metabolic syndrome

Obesity Reviews - Tập 11 Số 5 - Trang 380-388 - 2010
Marijke Schreurs1, Folkert Kuipers, Feike R. van der Leij
1Department of Pediatrics, Center for Liver, Digestive, and Metabolic Diseases, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands

Tóm tắt

SummaryInsulin sensitizers like metformin generally act through pathways triggered by adenosine monophosphate‐activated protein kinase. Carnitine palmitoyltransferase 1 (CPT1) controls mitochondrial β‐oxidation and is inhibited by malonyl‐CoA, the product of acetyl‐CoA carboxylase (ACC). The adenosine monophosphate‐activated protein kinase‐ACC‐CPT1 axis tightly regulates mitochondrial long‐chain fatty acid oxidation. Evidence indicates that ACC2, the isoform located in close proximity to CPT1, is the major regulator of CPT1 activity. ACC2 as well as CPT1 are therefore potential targets to treat components of the metabolic syndrome such as obesity and insulin resistance. Reversible inhibitors of the liver isoform of CPT1, developed to prevent ketoacidosis and hyperglycemia, have been found to be associated with side effects like hepatic steatosis. However, stimulation of systemic CPT1 activity may be an attractive means to accelerate peripheral fatty acid oxidation and hence improve insulin sensitivity. Stimulation of CPT1 can be achieved by elimination or inhibition of ACC2 activity and through activating transcription factors like peroxisome proliferator‐activated receptors and their protein partners. The latter leads to enhanced CPT1 gene expression. Recent developments are discussed, including a recently identified CPT1 isoform, i.e. CPT1C. This protein is highly expressed in the brain and may provide a target for new tools to prevent obesity.

Từ khóa


Tài liệu tham khảo

10.1172/JCI13505

10.1111/j.1432-1033.1997.00001.x

10.1074/jbc.272.16.10669

10.1172/JCI108764

10.1016/S0163-7827(01)00024-8

10.1152/ajpheart.00864.2003

10.1194/jlr.R800031-JLR200

10.2337/db07-0907

10.1016/S0167-4838(01)00147-9

10.1006/geno.2002.6845

10.1042/0264-6021:3410777

10.1074/jbc.270.15.8952

10.1074/jbc.271.12.6972

10.1006/jmcc.2000.1304

10.1016/j.ygeno.2007.08.004

10.1038/ijo.2008.123

10.1073/pnas.0602205103

10.1016/j.bbrc.2007.05.161

10.1074/jbc.M707965200

10.1038/nm873

10.1016/j.bcp.2008.11.020

10.1016/S1567-133X(02)00013-3

10.1042/bj3100853

10.1016/0014-5793(81)81152-0

10.1126/science.1056843

10.1042/bj2490409

10.1042/BST0290310

10.1210/edrv-6-4-590

10.1016/j.bbaexp.2004.06.006

10.1016/j.jmb.2005.09.097

10.1073/pnas.96.13.7473

10.1042/0264-6021:3540189

10.1161/01.RES.0000060700.55247.7C

10.1038/nm1756

10.1074/jbc.M210486200

10.1111/j.1432-1033.1985.tb08661.x

10.1002/hep.22101

10.1016/0026-0495(91)90214-H

10.1021/jm020979u

Valentini G, 2008, Effect of a selective and reversible hepatic CPT1 inhibitor on HOMA index and fasting blood glucose in diabetic type 2 patients, Diabetologia, 51, S23

Anderson RC, 1998, Carnitine palmitoyltransferase: a viable target for the treatment of NIDDM?, Curr Pharm Des, 4, 1

10.2337/diabetes.50.1.123

10.2337/db08-1078

10.2337/diacare.14.12.1180

10.2337/db08-1043

10.1073/pnas.132128899

10.1152/ajpregu.00862.2006

10.1021/bi052186q

10.1073/pnas.0505714102

10.1073/pnas.0706794104

10.1172/JCI27300

10.1073/pnas.92.9.4011

10.1073/pnas.97.4.1444

10.1152/ajpendo.1996.270.2.E299

10.1146/annurev.bi.52.070183.002541

10.1016/S0022-2275(20)37181-9

10.1073/pnas.96.24.13656

10.1074/jbc.M300553200

10.1073/pnas.0405238101

10.1073/pnas.0603115103

10.1016/j.ymgme.2005.07.021

10.1016/j.ymgme.2007.10.006

McCune SA, 1979, Mechanism responsible for 5‐(tetradecyloxy)‐2‐furoic acid inhibition of hepatic lipogenesis, J Biol Chem, 254, 10095, 10.1016/S0021-9258(19)86677-2

10.1074/jbc.M304481200

10.7164/antibiotics.47.23

Treadway JL, 2004, Effect of the acetyl‐CoA carboxylase inhibitor CP‐640186 on glycemic control in diabetic ob/ob mice, Diabetes, 53, 162

10.1111/j.1463-1326.2009.01078.x

10.1016/j.molcel.2004.11.034

10.1016/j.bbrc.2007.12.019

Thông tin
Thông tin xuất bản

Obesity Reviews

Tập 11 Số 5

380-388

Thông tin tác giả